An interventional study of LIVE-CLL personalised home-based physical activity program in Chronic Lymphocytic Leukemia and Fatigue Syndrome, Chronic, sponsored by University of Surrey. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by University of Surrey · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 139 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United Kingdom — 25 open to participants now, 46 under way, 20 of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · United Kingdom.
Among the 139 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United Kingdom, this one is the 109th largest by planned enrollment of the 130 interventional ones that give a count, is one of 6 that started in 2026, is one of 3 with no phase, reaches primary completion later than 21 of the 45 other live ones, and was the 139th registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →25 of the 139 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United Kingdom are open now. Recruiting first, the newest first:
CSL Behring · Sites in United Kingdom, United States, Belgium and 8 more countries
Ages 18+
AstraZeneca · Sites in United Kingdom, United States, Austria and 6 more countries
Ages 18–130
Eli Lilly and Company · Sites in United Kingdom, United States, Australia and 14 more countries
Ages 18+
BeOne Medicines · Sites in United Kingdom, United States, Australia and 14 more countries
Ages 18+
Nurix Therapeutics, Inc. · Sites in United Kingdom, United States, France and 2 more countries
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
139 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 44 · Phase 3 61 · Phase 4 4
First in 1993; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 200 across the 130 interventional studies, 93 across the 6 observational. Of the 83 that completed or were terminated, 45 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
117 of 139 have an industry lead sponsor. The 10 most frequent:
University of Surrey is the lead sponsor of 92 studies on the registry; 15 are open to participants now.
University of Surrey has 2 studies filed under Leukemia, Lymphocytic, Chronic, B-Cell — fewer than ten, so there is no comparison to draw.
9 of the studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United Kingdom that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT03836261Phase 3Acerta Pharma BVStudy of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL | 2027-04-30 |
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT05254743Phase 3Loxo Oncology, Inc.A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | 2027-10 |
| NCT04895436AbbVieStudy to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) | 2026-11 |
Add all 9 to your calendar (.ics) → With an account.
Among the 139 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this pilot study is to learn if a personalised, home-based online physical activity program (LIVE-CLL) is feasible for adults with chronic lymphocytic leukaemia (CLL) who experience fatigue. It will also learn if the program improves fatigue, symptoms and quality of life. The main questions it aims to answer are:
Can people with CLL be recruited to the program, attend their prescribed sessions, follow the prescribed exercise intensities, and stay in the study? Do fatigue, symptoms and quality of life change after 12 weeks of the program?
All participants will receive the LIVE-CLL program alongside their usual care. Researchers will compare measurements taken before and after the program.
Participants will:
Complete online fitness assessments and questionnaires by video call before and after the program Follow a personalised 12-week aerobic and strength program at home, 3 to 5 sessions per week, delivered through an exercise app Complete a short check-in form before each session and a wellbeing form each week, so the program can be adjusted
Background and rationale
Compared with people with solid tumours, people with haematological malignancies, including CLL, have greater physical deconditioning, worse quality of life and a heavier symptom burden, especially fatigue. In CLL, fatigue is common in treatment-naïve patients, more severe in treated patients, and an independent predictor of poor quality of life. Preliminary survey data collected with the CLL Support Association (approximately 1,000 respondents) show that fatigue prevalence and severity increased between 2022 and 2024, and that patients are rarely referred to services that can address it.
Cancer-related fatigue has many causes. In treated CLL, the BTK inhibitors (e.g., ibrutinib) and BCL2 inhibitors (e.g., venetoclax) have off-target effects on skeletal and cardiac muscle, which may contribute to fatigue and to the higher risk of cardiac events. Fatigue and frailty are also more common in treatment-naïve CLL than in the general population. The investigators' published metabolic biomarker data suggest that CLL cells may use lipid-based fuels that skeletal and cardiac muscle depend on. Together, these mechanisms suggest that fatigue in CLL may differ from fatigue in solid tumours. CLL patients may therefore benefit from a disease-specific, symptom-targeted approach, given at diagnosis (prehabilitation) and when treatment starts (rehabilitation), rather than generic exercise oncology programs.
Patient and public involvement
The intervention design is based on a 2022 patient focus group and online survey of people with CLL. These covered exercise motivations and barriers, intervention preferences, the role of diet and nutrition, and research priorities. It was also refined using feedback from 60 participants who completed a previous 6-month exercise trial run by the investigators. That feedback showed demand for lifestyle approaches that target symptoms such as fatigue and can be delivered in the community.
Study design
This is a prospective, single-arm, pre-test/post-test pilot feasibility study. Formal power calculations were not performed. The target sample of 30 per subgroup (treatment-naïve and on-treatment) follows standard recommendations for pilot studies that aim to generate estimates for powering a definitive trial. Participants are recruited when they are unlikely to change treatment pathway during the study (e.g., moving from watch-and-wait to treatment, or finishing fixed-duration venetoclax). Recruitment is expected to run at 6-10 participants per 4-week period over a 37-week window.
Pre-participation screening
The FACIT-Fatigue is completed online. Eligible participants then have a virtual screening session on MS Teams, which covers medical history, cancer history, emergency contacts and where they will exercise. Exercise readiness is assessed with the PAR-Q+. Participants flagged for further evaluation complete the ePARmed-X+ and need medical clearance from their healthcare provider. Any intensity restrictions the provider recommends are built into the exercise prescription. A Clinical Exercise Physiologist then writes a medical summary form for use during assessments and program delivery.
Remote assessment procedures
Assessments are done by video call with two trained exercise professionals: a primary assessor and a secondary assessor, who records results and supports safety procedures. Before testing, the team checks the participant's home environment and equipment and chooses a suitable test battery. Whether each assessment can be completed remotely is itself a feasibility measure, and not being able to complete a test does not exclude a participant. Physical performance is assessed with standardised online fitness assessment protocols for exercise oncology (Daun et al., 2024). Resting heart rate and blood pressure are measured with the participant's own devices or by assessor-guided pulse palpation. A wrist-worn activity/heart-rate monitor may be posted to participants. Anthropometrics are self-reported using standardised instructions, or taken from a recent clinical record. Patient-reported measures are collected through Qualtrics. Dietary intake is assessed with a 7-day food diary and the short-form food frequency questionnaire. Comorbidity burden is assessed with the CLL Comorbidity Index (CLL-CI).
Intervention
Exercise prescription follows the Sasso et al. (2015) framework for exercise-oncology research and ACSM exercise prescription guidelines, in line with UK Chief Medical Officers' physical activity guidelines. A Clinical Exercise Physiologist writes each program. Programs combine aerobic and resistance exercise to target the limitations found at baseline. Intensity ranges from low (e.g., walking) to moderate (e.g., jogging), based on PAR-Q+ safety zones, and is regulated with ratings of perceived exertion (Borg 6-20 or CR-10). Resistance is adapted to the equipment the participant has, including household items. Programs are delivered through Physitrack, a web and mobile exercise prescription platform used across more than 60 NHS trusts. Participants log in with study-issued IDs, so no personal data is held on the platform. Optional live online group classes are run by a Clinical Exercise Physiologist with a second team member present.
Programs are adjusted continuously based on participant reports. Before each session, participants complete a readiness form covering new injuries, illness and fatigue on a 0-10 scale. If fatigue is above 7/10, or new symptoms are reported, an alternative low-intensity session is offered and the participant is advised to contact the team. A more detailed weekly physical and mental wellbeing form guides progression or regression, and the team arranges a video or phone call if there are wellbeing concerns. An onboarding call introduces the platform before the intervention starts.
Safety monitoring
Self-directed sessions are not monitored in real time. Team support is available 09:00-17:00, Monday to Friday. Out-of-hours risk is managed by:
Giving explicit emergency guidance (call 999; use NHS 111, the GP or the haematology team for urgent non-emergency concerns) Asking participants to tell a contact before each session and keep a phone nearby Encouraging sessions during team hours, especially early in the program Requiring a friend or family member to be present, and team supervision instead of self-directed sessions, for participants classed as weak or frail at baseline
During live sessions, one team member stays with the participant while the second calls emergency services and the emergency contacts.
Exercise-related adverse events are collected from the first exercise test to the last. They are graded with CTCAE v5.0 (or mild to fatal where no CTCAE grading exists) and recorded as related or unrelated to study procedures. Expected minor effects (fatigue, muscle soreness, joint or lower back pain, leg cramps) are not recorded as adverse events. Serious adverse events are reported to the University Ethics Committee within 24 hours. The exercise physiologist is a Level 4 Cancer Rehabilitation Specialist.
Statistical analysis
Participant characteristics will be summarised as mean ± SD or median (IQR), depending on distribution. Feasibility will be judged against pre-set thresholds for recruitment, adherence, compliance and retention. Pre-to-post changes in continuous outcomes will be analysed with linear mixed models, using non-parametric alternatives if data are not normally distributed. Categorical outcomes will be analysed with Pearson chi-square tests. Statistical significance is set at p ≤ 0.05, and trends are noted at p ≤ 0.10. Effect estimates will be used to inform the sample size for a future controlled trial.
Ethics, data management and funding
The study is reviewed by the University of Surrey Ethics Committee. Participants are not recruited through the NHS, so NHS REC review is not required. Data are collected through Qualtrics, moved to secure University servers within 2 weeks, and pseudonymised. Identifiable data are stored separately with restricted access. Records are kept for at least 10 years. The study is funded by Blood Cancer UK.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
No access to the digital platforms used to assess participants and deliver the program (e.g., internet-connected device for video calls and the exercise app)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults with CLL and fatigue (FACIT-Fatigue \<34), both treatment-naïve and on treatment, receive a personalised 12-week home-based online physical activity program alongside usual care.
Behavioral: LIVE-CLL personalised home-based physical activity program
A 12-week, semi-supervised, home-based aerobic and resistance exercise program prescribed by a Clinical Exercise Physiologist using ACSM guidelines. It targets the physical limitations found at baseline assessment. Sessions are 3 to 5 per week, at low to moderate intensity regulated by rating of perceived exertion (Borg scale). They are delivered through the Physitrack app, with optional live online group classes. A readiness check before each session and a weekly wellbeing form are used to progress, regress or replace sessions.
Recruitment rate
Number of participants enrolled per 4-week period, and total enrolled against the target of 60. The target rate is 6 to 10 participants per 4 weeks.
Time frame: Over the 37-week recruitment period
Adherence to prescribed sessions
Percentage of prescribed weekly exercise sessions completed, recorded on the Physitrack platform. Feasibility is met if adherence is above 85%.
Time frame: Baseline to week 12
Compliance with prescribed exercise intensity and duration
Percentage of participants who complete sessions at the prescribed intensity (rating of perceived exertion) and duration, based on session logs. Feasibility is met if more than 80% comply.
Time frame: Baseline to week 12
Retention
Percentage of enrolled participants who drop out before the post-intervention assessment. Feasibility is met if fewer than 15% drop out.
Time frame: Baseline to week 12
Completion of remote assessments
Proportion of planned online physical assessments that are completed successfully.
Time frame: Baseline and week 12 (post-intervention)
FACIT-Fatigue
Functional Assessment of Chronic Illness Therapy - Fatigue scale. Range 0-52; higher scores mean less fatigue.
Time frame: Baseline and week 12 (post-intervention)
Fatigue Assessment Scale (FAS)
Range 10-50; higher scores mean more fatigue.
Time frame: Baseline and week 12 (post-intervention)
Fatigue Severity Scale (FSS)
Mean item score, range 1-7; higher scores mean more severe fatigue.
Time frame: Baseline and week 12 (post-intervention)
Health-related quality of life (EORTC QLQ-C30)
Global health status, functional scales and symptom scales, each scored 0-100. Higher functional and global scores mean better function. Higher symptom scores mean more symptoms.
Time frame: Baseline and week 12 (post-intervention)
CLL-specific quality of life (EORTC QLQ-CLL17)
Symptom burden, physical condition/fatigue, and worries/fears scales, each scored 0-100. Higher scores mean more problems.
Time frame: Baseline and week 12 (post-intervention)
Lymphoma-specific quality of life (FACT-Lym)
Total score 0-168; higher scores mean better quality of life.
Time frame: Baseline and week 12 (post-intervention)
Anxiety and depression (HADS)
Hospital Anxiety and Depression Scale. Anxiety and depression subscales, each 0-21; higher scores mean more symptoms.
Time frame: Baseline and week 12 (post-intervention)
Cognitive function (FACT-Cog)
Perceived cognitive impairment and related subscales; higher scores mean better cognitive function.
Time frame: Baseline and week 12 (post-intervention)
Sleep quality (Pittsburgh Sleep Quality Index)
Global score 0-21; higher scores mean worse sleep quality.
Time frame: Baseline and week 12 (post-intervention)
Geriatric vulnerability (G8)
Range 0-17; a score of 14 or below indicates geriatric vulnerability.
Time frame: Baseline and week 12 (post-intervention)
Leisure-time physical activity (Godin Leisure-Time Exercise Questionnaire)
Leisure Score Index; higher scores mean more activity.
Time frame: Baseline and week 12 (post-intervention)
Physical activity level (Stanford Brief Activity Survey)
Categorical activity level, from inactive to very active.
Time frame: Baseline and week 12 (post-intervention)
Lower-body strength (30-second sit-to-stand test)
Number of repetitions in 30 seconds.
Time frame: Baseline and week 12 (post-intervention)
Aerobic endurance (2-minute step test)
Number of steps in 2 minutes.
Time frame: Baseline and week 12 (post-intervention)
Balance (single-leg stance test)
Time in seconds.
Time frame: Baseline and week 12 (post-intervention)
Lower-body flexibility (chair sit-and-reach test)
Distance in centimetres.
Time frame: Baseline and week 12 (post-intervention)
Shoulder flexion range of motion
Degrees
Time frame: Baseline and week 12 (post-intervention)
Resting heart rate and blood pressure
Beats per minute; mmHg.
Time frame: Baseline and week 12 (post-intervention)
Body mass index
kg/m², from self-reported height and weight.
Time frame: Baseline and week 12 (post-intervention)
Dietary quality
Dietary quality score from the short-form food frequency questionnaire (SFFFQ), plus energy and macronutrient intake from a 7-day food diary.
Time frame: Baseline and week 12 (post-intervention)
Exercise-related adverse events
Number of participants with adverse events related to exercise testing or training, graded with CTCAE v5.0.
Time frame: From first exercise test to post-intervention assessment (12 weeks)
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymised individual participant data underlying the published results (feasibility metrics, questionnaire scores, physical performance and dietary data) will be shared for participants who consented to data sharing. No directly identifiable information will be shared.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code
Time frame: Data will be available after publication of the primary results and for at least 10 years, in line with the study's data retention policy.
Access criteria: Data will be made available to researchers who submit a methodologically sound proposal, on request to the Principal Investigator (d.bartlett@surrey.ac.uk). Access will require a data sharing agreement with the University of Surrey. Data will be shared only for participants who consented to data sharing.
Start is estimated for Dec 2026; primary completion for Nov 2027, 11 months later.
Of 37 non-industry interventional studies with no phase under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 134. This study's planned 11 months is below that.
Counting every sponsor, half of 39 studies reached it within 42 months; a quarter within 27 and three quarters within 134.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Leukemia, Lymphocytic, Chronic, B-Cell →
University of Surrey